| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lidia Bakota, Roland Brand. Why kiss-and-hop explains that tau does not stabilize microtubules and does not interfere with axonal transport (at physiological conditions). Cytoskeleton (Hoboken, N.J.). 2023-09-11. PMID:37694806. |
post-translational modifications of tau have been implicated in the development of tauopathies characterized by defects in axonal transport, neuronal atrophy, and microtubule disassembly. |
2023-09-11 |
2023-10-07 |
Not clear |
| b' Dorota Kon\\xc3\\xad\\xc4\\x8dkov\\xc3\\xa1, Kate\\xc5\\x99ina Men\\xc5\\xa1\\xc3\\xadkov\\xc3\\xa1, Kate\\xc5\\x99ina Kl\\xc3\\xad\\xc4\\x8dov\\xc3\\xa1, Monika Chud\\xc3\\xa1\\xc4\\x8dkov\\xc3\\xa1, Michaela Kaiserov\\xc3\\xa1, Hana P\\xc5\\x99ikrylov\\xc3\\xa1, Pavel Otruba, Martin Nevrl\\xc3\\xbd, Petr Hlu\\xc5\\xa1t\\xc3\\xadk, Eva H\\xc3\\xa9nykov\\xc3\\xa1, Michal Kaleta, David Friedeck\\xc3\\xbd, Radoslav Mat\\xc4\\x9bj, Miroslav Strnad, Ond\\xc5\\x99ej Nov\\xc3\\xa1k, Lucie Pl\\xc3\\xadhalov\\xc3\\xa1, Raymond Rosales, Carlo Colosimo, Petr Ka\\xc5\\x88ovsk\\xc3\\xb. Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies: A prospective, open, cross-correlation study. Journal of neurochemistry. 2023-09-08. PMID:37680022.' |
thus said, this present research aimed to identify biomarkers in the cerebrospinal fluid (csf) and serum (α-synuclein [α-syn], tau protein [t-tau], phosphorylated tau protein [p-tau], β-amyloid [aβ], clusterin, chromogranin a [chromogra], cystatin c [cyst c], neurofilament heavy chains [nfh], phosphorylated form of neurofilament heavy chains [pnf-h], and ratio of tau protein/amyloid beta [ind tau/aβ]) that could help in the differential diagnosis and differentiation of the defined groups of α-synucleinopathies and four-repeat (4r-) tauopathies characterized by tau protein isoforms with four microtubule-binding domains. |
2023-09-08 |
2023-10-07 |
Not clear |
| Peng Wang, D Eric Anderson, Yihong Y. PI3K-AKT activation resculpts integrin signaling to drive filamentous tau-induced proinflammatory astrogliosis. Research square. 2023-09-07. PMID:37674732. |
background microtubule-binding protein tau is a misfolding-prone protein associated with tauopathies. |
2023-09-07 |
2023-10-07 |
mouse |
| Yongqi Huang, Jitao Wen, Lisa-Marie Ramirez, Eymen Gümüşdil, Pravin Pokhrel, Viet H Man, Haiqiong Ye, Yue Han, Yunfei Liu, Ping Li, Zhengding Su, Junmei Wang, Hanbin Mao, Markus Zweckstetter, Sarah Perrett, Si Wu, Meng Ga. Methylene blue accelerates liquid-to-gel transition of tau condensates impacting tau function and pathology. Nature communications. vol 14. issue 1. 2023-09-06. PMID:37673952. |
preventing tau aggregation is a potential therapeutic strategy in alzheimer's disease and other tauopathies. |
2023-09-06 |
2023-10-07 |
Not clear |
| Maxwell Eisenbaum, Andrew Pearson, Camila Ortiz, Michael Mullan, Fiona Crawford, Joseph Ojo, Corbin Bachmeie. ApoE4 expression disrupts tau uptake, trafficking, and clearance in astrocytes. Glia. 2023-09-05. PMID:37668005. |
tauopathies are a collection of neurodegenerative diseases characterized by the accumulation of pathogenic aggregates of the microtubule-associated protein tau. |
2023-09-05 |
2023-09-07 |
mouse |
| Maxwell Eisenbaum, Andrew Pearson, Camila Ortiz, Michael Mullan, Fiona Crawford, Joseph Ojo, Corbin Bachmeie. ApoE4 expression disrupts tau uptake, trafficking, and clearance in astrocytes. Glia. 2023-09-05. PMID:37668005. |
despite the prevalence and diversity of tau astrogliopathy in tauopathies, the interactions between astrocytes and tau in the brain, and the influence of neurodegenerative genetic risk factors like the apolipoprotein e4 (apoe4) isoform, are largely unknown. |
2023-09-05 |
2023-09-07 |
mouse |
| Ruizhi Wang, Kun Ping Lu, Xiao Zhen Zho. Function and regulation of cis P-tau in the pathogenesis and treatment of conventional and nonconventional tauopathies. Journal of neurochemistry. 2023-08-28. PMID:37638382. |
conventional tauopathies are a group of disease characterized by tau inclusions in the brains, including alzheimer's disease (ad), pick's disease (pid), progressive supranuclear palsy (psp), corticobasal degeneration (cbd), and certain types of frontotemporal dementia (ftd), among which ad is the most prevalent. |
2023-08-28 |
2023-09-07 |
Not clear |
| George S Bloom, Andrés Norambuen. Dysregulation of mTOR by tau in Alzheimer's disease. Cytoskeleton (Hoboken, N.J.). 2023-08-28. PMID:37638691. |
interest in tau rose by the late 1980's, when it was shown to be the principal subunit of the neurofibrillary tangles (nfts) that accumulate in alzheimer's disease (ad) brain, and achieved new heights by the late 1990's, when numerous tau mutations were found to be highly penetrant for ad-related disorders that also are associated with nfts and came to be known as non-alzheimer's tauopathies. |
2023-08-28 |
2023-09-07 |
Not clear |
| Junhao Li, Amit Kumar, Bengt Långström, Agneta Nordberg, Hans Ågre. Insight into the Binding of First- and Second-Generation PET Tracers to 4R and 3R/4R Tau Protofibrils. ACS chemical neuroscience. 2023-08-28. PMID:37639522. |
in this study, we use multiple approaches, including docking, molecular dynamics, and metadynamics simulations, to investigate the binding mechanism of 10 first- and second-generations of pet tracers for psp tau and compare their binding in cortical basal degeneration (cbd) and ad tauopathies. |
2023-08-28 |
2023-09-07 |
Not clear |
| Zachary A Sorrentino, Giavanna Paterno, Benoit I Giasson, Julian E Bailes, John M Lee, Brandon Lucke-Wol. Differentiating pathologic tau in chronic traumatic encephalopathy (CTE) from other tauopathies: A potential antibody panel assessment. Journal of neuropathology and experimental neurology. 2023-08-28. PMID:37639632. |
differentiating pathologic tau in chronic traumatic encephalopathy (cte) from other tauopathies: a potential antibody panel assessment. |
2023-08-28 |
2023-09-07 |
Not clear |
| Mirjam Brackhan, Marina Arribas-Blazquez, Isabel Lastres-Becke. Aging, NRF2, and TAU: A Perfect Match for Neurodegeneration? Antioxidants (Basel, Switzerland). vol 12. issue 8. 2023-08-26. PMID:37627559. |
finally, we investigated the interconnection between nrf2 and tau and the relevance of alterations in the nrf2 signaling pathway in both primary and secondary tauopathies. |
2023-08-26 |
2023-09-07 |
Not clear |
| Esteban Cruz, Rebecca M Nisbet, Jürgen Göt. Break and accelerator-The mechanics of Tau (and amyloid) toxicity. Cytoskeleton (Hoboken, N.J.). 2023-08-26. PMID:37632370. |
aggregates of the microtubule-associated protein tau define more than a dozen primary tauopathies, and together with amyloid-β, the secondary tauopathy alzheimer's disease (ad). |
2023-08-26 |
2023-09-07 |
Not clear |
| Jennifer M Zupancic, Matthew D Smith, Hanna Trzeciakiewicz, Mary E Skinner, Sean P Ferris, Emily K Makowski, Michael J Lucas, Nikki McArthur, Ravi S Kane, Henry L Paulson, Peter M Tessie. Quantitative flow cytometric selection of tau conformational nanobodies specific for pathological aggregates. Frontiers in immunology. vol 14. 2023-08-25. PMID:37622125. |
the isolated nanobodies demonstrate conformational specificity for tau aggregates in brain samples from both a transgenic mouse model and human tauopathies. |
2023-08-25 |
2023-09-07 |
mouse |
| Gayatri Dev. The tauopathies. Handbook of clinical neurology. vol 196. 2023-08-24. PMID:37620072. |
tauopathies are a clinically and neuropathologically heterogeneous group of neurodegenerative disorders, characterized by abnormal tau aggregates. |
2023-08-24 |
2023-09-07 |
Not clear |
| Gayatri Dev. The tauopathies. Handbook of clinical neurology. vol 196. 2023-08-24. PMID:37620072. |
primary tauopathies are classified based on tau isoform and cell types where pathology predominates. |
2023-08-24 |
2023-09-07 |
Not clear |
| Francesco Panza, Vincenzo Solfrizzi, Antonio Daniele, Madia Lozupon. Passive tau-based immunotherapy for tauopathies. Handbook of clinical neurology. vol 196. 2023-08-24. PMID:37620094. |
tauopathies are heterogeneous clinicopathological entities characterized by abnormal neuronal and/or glial inclusions of the microtubule-binding protein tau. |
2023-08-24 |
2023-09-07 |
Not clear |
| Francesco Panza, Vincenzo Solfrizzi, Antonio Daniele, Madia Lozupon. Passive tau-based immunotherapy for tauopathies. Handbook of clinical neurology. vol 196. 2023-08-24. PMID:37620094. |
in secondary tauopathies, i.e., alzheimer's disease (ad), tau deposition can be observed, but tau may coexist with another protein, i.e., amyloid-β. |
2023-08-24 |
2023-09-07 |
Not clear |
| Bess Fros. Alzheimer's disease and related tauopathies: disorders of disrupted neuronal identity. Trends in neurosciences. 2023-08-17. PMID:37591720. |
in alzheimer's disease (ad) and related tauopathies, evidence suggests that pathogenic forms of tau drive neurodegeneration via neuronal cell cycle re-entry. |
2023-08-17 |
2023-09-07 |
human |
| Bess Fros. Alzheimer's disease and related tauopathies: disorders of disrupted neuronal identity. Trends in neurosciences. 2023-08-17. PMID:37591720. |
in this review, i delve into mechanistic parallels between tauopathies, cancer, and development, and highlight the role of tau in cancer and in the developing brain. |
2023-08-17 |
2023-09-07 |
human |
| Yu Zou, Bote Qi, Jingwang Tan, Lulu Guan, Qingwen Zhang, Yunxiang Sun, Fengjuan Huan. Deciphering the Inhibitory Mechanism of Naphthoquinone-Dopamine on the Aggregation of Tau Core Fragments PHF6* and PHF6. ACS chemical neuroscience. 2023-08-16. PMID:37585669. |
the formation of neurofibrillary tangles by abnormal aggregation of tau protein is considered to be an important pathological characteristic of tauopathies, including alzheimer's disease and chronic traumatic encephalopathy. |
2023-08-16 |
2023-09-07 |
Not clear |